Clinical Trial News and Research

RSS

Spectrum Pharmaceuticals signs co-development and commercialization agreement with TopoTarget A/S

Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology, today announced that it has entered into a co-development and commercialization agreement with TopoTarget A/S for Belinostat, a novel histone deacetylase (HDAC) inhibitor.

2 Feb 2010

Decision Resources: Benlysta to garner more than $500M in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, following its expected regulatory approval in 2011 in the United States and Europe, Human Genome Sciences/GlaxoSmithKline's Benlysta will garner sales of more than $500 million in 2018 in the systemic lupus erythematosus drug market.

2 Feb 2010

Positive results from Phosphagenics' TPM Phase 1B clinical study for transdermal delivery of oxycodone

Phosphagenics Limited today announced positive results from a Phase 1B clinical study using the Company’s patented TPM™ (Targeted Penetration Matrix) for the transdermal delivery of oxycodone. The results of the successful trial demonstrate that daily application of a TPM™ patch delivers therapeutic levels of oxycodone into the blood stream in a reproducible, consistent and sustained manner.

2 Feb 2010

Long-chain omega-3 polyunsaturated fatty acids may reduce risk of psychotic disorders

Individuals at extremely high risk of developing psychosis appear less likely to develop psychotic disorders following a 12-week course of fish oil capsules containing long-chain omega-3 polyunsaturated fatty acids, according to a report in the February issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

2 Feb 2010

Pervasis Therapeutics reaches agreement with FDA on pivotal Phase 3 clinical trial for Vascugel

Pervasis Therapeutics, Inc. today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of a pivotal Phase 3 clinical trial for Vascugel®, an investigational new drug for the prevention of hemodialysis access graft failure.

2 Feb 2010

Romark Laboratories commences enrollment in Alinia clinical trial for acute uncomplicated influenza

Romark Laboratories announced that it has initiated enrollment of patients in a clinical trial of Alinia® (nitazoxanide) for treating acute uncomplicated influenza including illness caused by the currently circulating H1N1 strain.

1 Feb 2010

Congress faces one-month deadline on doctor payment fix

The doctor payment fix and several marketplace issues, such as insurance red tape and malpractice cases, continue to loom while health care reform efforts stall.

1 Feb 2010

FDA approves Allergan's JUVÉDERM XC dermal filler

Allergan, Inc. today announced the U.S. Food and Drug Administration’s (FDA) approval of JUVÉDERM® XC, a new formulation of the currently FDA-approved JUVÉDERM® dermal filler and the latest advancement in hyaluronic acid (HA) dermal fillers.

1 Feb 2010

Managing Myeloma reviews past accomplishments; discusses future goals in evolving therapeutic landscape

Managing Myeloma (www.ManagingMyeloma.com) convened the 2010 Multidisciplinary Advisory Board on January 16, 2010 to review the past 18 months and discuss the educational and practical needs of myeloma practitioners in an evolving therapeutic landscape.

1 Feb 2010

DSG’s eCaseLink EDC system employed in clinical trials for treatment of chronic kidney disease

DSG’s eCaseLink™ Electronic Data Capture (EDC) and data management are currently being used by a biotechnology company for two current phase 2 and phase 2a clinical trials for treatments of progressive and chronic kidney disease.

1 Feb 2010

Ipsen reports consolidated group sales of €1,032.8M for 2009

Ipsen reported today its sales for the fourth quarter and full year 2009.

1 Feb 2010

New vaccine effective in preventing TB in HIV patients

Investigators from Dartmouth Medical School (DMS) have reported results of a clinical trial showing that a new vaccine against tuberculosis, Mycobacterium vaccae (MV), is effective in preventing tuberculosis in people with HIV infection.

30 Jan 2010

FDA approves new drug combination for hormone positive and HER2-positive advanced breast cancer

The U.S. Food and Drug Administration today approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated.

30 Jan 2010

Diffusion Pharmaceuticals closes on $5.9M in additional private financing

Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing first-in-class drugs to treat serious or life-threatening unmet medical conditions, today announced that it closed on $5.9 million in additional private financing during the second half of 2009, bringing the total the company raised in 2009 to $7.1 million.

29 Jan 2010

ECCO supports its member organisations' proposals for adapting the EU Clinical Trials Directive

In response to a European Commission consultation on the EU Clinical Trials Directive, ECCO - the European CanCer Organisation - has supported proposals by its member organisations for adapting the Directive's requirements to reflect practical necessities in cancer research and treatment.

29 Jan 2010

Invatec welcomes first clinical results of Drug Eluting Balloon

Invatec, a comprehensive innovator of interventional products, welcomed the first clinical results of the Drug Eluting Balloon (DEB), IN.PACT Amphirion, for complex Critical Limb Ischemia (CLI) in Below the Knee (BtK).

29 Jan 2010

Clinical trial data of Medtronic Arctic Front CryoAblation Catheter System for treating AF to be presented

Medtronic, Inc. announced today pivotal data for the Medtronic Arctic Front® CryoAblation Catheter System will be presented as a late breaking clinical trial at the 59th Annual Scientific Session of the American College of Cardiology on Monday, March 15 at 8 a.m. ET. The STOP-AF (Sustained Treatment of Paroxysmal Atrial Fibrillation) clinical trial is evaluating the safety and efficacy of the Arctic Front CryoAblation Catheter System for paroxysmal atrial fibrillation (AF) patients.

29 Jan 2010

Merge Healthcare deploys etrials eDiary 5.0 platform for global urology clinical trial

Merge Healthcare has successfully deployed its etrials eDiary 5.0 platform to conduct a global Phase II urology clinical trial involving 750 patients for one of the largest pharmaceutical companies in the world. Merge was awarded the project because of its eDiary technology, experience in global ePRO (electronic patient reported outcomes) trials and ability to manage the complex logic required by this study. Underway in 22 countries on 3 continents and in 34 languages, the trial also utilizes Merge’s new eDiary Inventory Module to track shipping and supply of study devices in real-time.

29 Jan 2010

OMT, a viable option for treating back pain in the third trimester of pregnancy

For many pregnant women, it's inevitable. As their pregnancy progresses, tasks that involve the low back often get more difficult. It is harder to bend over, lift, sit or walk for long periods of time, and back pain increases. Treating back pain, and improving daily function relative to tasks that involve the low back is a challenge because pregnant women are limited to treatments that will not create problems for their developing baby.

29 Jan 2010

Conatus Pharmaceuticals initiates combination trial of CTS-1027 with pegylated interferon and ribavirin for HCV

Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys®) and ribavirin (Copegus®) in refractory HCV patients. Antiviral activity, safety and tolerability of the triple combination will be assessed after up to 48 weeks of therapy.

28 Jan 2010

Clinical Trial News and Research

Spectrum Pharmaceuticals signs co-development and commercialization agreement with TopoTarget A/S

Decision Resources: Benlysta to garner more than $500M in 2018

Positive results from Phosphagenics' TPM Phase 1B clinical study for transdermal delivery of oxycodone

Long-chain omega-3 polyunsaturated fatty acids may reduce risk of psychotic disorders

Pervasis Therapeutics reaches agreement with FDA on pivotal Phase 3 clinical trial for Vascugel

Romark Laboratories commences enrollment in Alinia clinical trial for acute uncomplicated influenza

Congress faces one-month deadline on doctor payment fix

FDA approves Allergan's JUVÉDERM XC dermal filler

Managing Myeloma reviews past accomplishments; discusses future goals in evolving therapeutic landscape

DSG’s eCaseLink EDC system employed in clinical trials for treatment of chronic kidney disease

Ipsen reports consolidated group sales of €1,032.8M for 2009

New vaccine effective in preventing TB in HIV patients

FDA approves new drug combination for hormone positive and HER2-positive advanced breast cancer

Diffusion Pharmaceuticals closes on $5.9M in additional private financing

ECCO supports its member organisations' proposals for adapting the EU Clinical Trials Directive

Invatec welcomes first clinical results of Drug Eluting Balloon

Clinical trial data of Medtronic Arctic Front CryoAblation Catheter System for treating AF to be presented

Merge Healthcare deploys etrials eDiary 5.0 platform for global urology clinical trial

OMT, a viable option for treating back pain in the third trimester of pregnancy

Conatus Pharmaceuticals initiates combination trial of CTS-1027 with pegylated interferon and ribavirin for HCV

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer